Using tranexamic acid to prevent bleeding during surgery for spinal tumors in lung cancer patients
Tranexamic Acid Use for Bleeding Prevention in the Surgical Treatment of Metastatic Spinal Tumor in Lung Cancer Patients: a Triple Blinded, Randomized Controlled Trial to Assess the Efficacy of Tranexamic Acid for Hemostasis
This study tests whether giving tranexamic acid can help lung cancer patients with spinal tumors lose less blood during surgery compared to those who get a saline solution.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 10 Years to 80 Years |
| Sex | All |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06023212 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of tranexamic acid in reducing blood loss during and after surgical procedures for patients with metastatic spinal tumors related to lung cancer. It compares outcomes between patients receiving tranexamic acid and those receiving a saline solution. The focus is on patients undergoing separation surgery for solitary spinal neoplasms. The study aims to address the significant risk of massive blood loss associated with these surgeries.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with metastatic carcinoma of the thoracolumbar spine who are undergoing separation surgery for a solitary neoplasm.
Not a fit: Patients with abnormal coagulation function, allergies to tranexamic acid, or those with neoplasms involving multiple spine segments may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce perioperative and postoperative bleeding, improving patient outcomes and recovery times.
How similar studies have performed: Other studies have shown promising results with tranexamic acid in reducing bleeding in various surgical contexts, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed as metastatic carcinoma of the thoracolumbar spine * solitary neoplasm involve only one segment of spine * patients underwent separation surgery Exclusion Criteria: * coagulation function was abnormal preoperatively * patients are allergic to tranexamic acid * neoplasm involve more than one segment of spine * patients with rich blood supply who need embolization
Where this trial is running
Hangzhou, Zhejiang
- the Second Affiliated Hospital Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Hengyuan Li, MD
- Email: hengyuanxiang007@163.com
- Phone: 13616519278
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.